News and FDA Updates for Santarus (NASDAQSNTS), Wu

thvi3hbohtv

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com
On 12/22/09, Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company,[link widoczny dla zalogowanych], announced it has received the $20 million milestone payment previously announced on December 1, 2009 relating to the approval of ZEGERID OTC? (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its over-the-counter (OTC) licensing agreement with Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.
On 12/22/09,[link widoczny dla zalogowanych], WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology,[link widoczny dla zalogowanych], and medical-device research and development outsourcing company, with operations in China and the United States,[link widoczny dla zalogowanych], announced it had been selected for the Deloitte Technology Fast 500 Asia Pacific 2009 List,[link widoczny dla zalogowanych], the only company in China to receive this award for the past six years.